// Company Overview //
| Stock Name | 巨子生物 |
|---|---|
| Stock Code | 02367 |
| Company Full Name | 巨子生物 |
| Industry | 醫療保健 |
| Principal Activities | 主要在中國從事研究、開發、制造和銷售基於生物活性成分的皮膚護理產品及健康食品。 |
| Listing Date | 2022-11-04 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | No data |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國陜西省西安市長安區上林苑七路1855號 |
| Business Address (Hong Kong) | No data |
| Place of Incorporation | No data |
| Listing Method | No data |
| Listing Board | Main Board |
| Website | http://www.xajuzi.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
// Offering Information //
| Offering Mechanism | 未知 |
|---|---|
| Clawback Tiers | No data |
| Prospectus Date | 2022-10-25 |
| Offer Price | HK$ 24.30 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 200 shares |
| Entry Threshold | HK$ 4,860 |
| Par Value | No data |
| Global Offering Shares | — |
| HK Public Offering Shares | — (0%) |
| International Placing Shares | — (0%) |
| Offer Ratio | No data |
| Total Shares Post-IPO | No data |
| Total Global Offering Size | HK$ — |
| Public Offering Size | HK$ — (0%) |
| Oversubscription Multiple | —x |
| Valid Applications | — |
| Accepted Applications | — |
| Reallocation | No |
| Total Funds Raised | HK$ 54,947,160 |
| Greenshoe (Over-allotment Option) | No data |
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
|---|---|
| Pre-IPO Valuation (Last Round) | No data |
| P/E Ratio | 23.77 |
| Profit/Loss Status | No data |
| Period-End Cash Balance | No data |
| Listing Expenses | ~HK$ 85,100,000 |
| Listing Expenses / Funds Raised | No data |
| Total Pre-IPO Investment | No data |
// First Day Performance
| First Day Close | Loading... |
|---|---|
| First Day Open | HK$ 26.0 |
| First Day Change | 9.88% |
| First Day Volume | 7243000.0 |
| First Day Turnover | 202303000.0 |
// Price Chart //
Loading...
// Use of Proceeds
| Use of Proceeds | 1、約11%的所得款項凈額（即54.5百萬港元）用于研發投資以通過招聘擴大我們的研發團隊、擴展我們的研發設施及進行測試和驗證研究； 2、約28%的所得款項凈額（即138.8百萬港元）用于擴展與我們的產品組合及生物活性成分有關的生產能力； 3、約46%的所得款項凈額（即228.1百萬港元），用于增強我們的全渠道銷售及經銷網絡，并開展以科學和知識為導向的營銷活動以提高我們的品牌知名度； 4、約5%的所得款項凈額（即24.8百萬港元）用于提升我們運營及信息系統； 5、約10%的所得款項凈額（即49.6百萬港元）用作營運資金及一般公司用途。 |
|---|
// Underwriting Syndicate //
联席保荐人 (2)
高盛（亚洲）有限责任公司
中国国际金融香港证券有限公司
整体协调人 (2)
高盛（亚洲）有限责任公司
中国国际金融香港证券有限公司
联席账簿管理人 (3)
高盛（亚洲）有限责任公司
中国国际金融香港证券有限公司
华泰金融控股（香港）有限公司
联席牵头经办人 (6)
高盛（亚洲）有限责任公司
中国国际金融香港证券有限公司
华泰金融控股（香港）有限公司
广发证券(香港)经纪有限公司
富途证券国际（香港）有限公司
元库证券有限公司
// Cornerstone Investors //
This stock has no cornerstone investors.
// Directors & Management //
| Chairman | 嚴建亞 |
|---|---|
| Company Secretary | 嚴鈺博;歐陽麗妮 |
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | 范代娣及關連人士(60.4%) |
|---|
// Allotment Benchmarks //
Pool A (Small Subscriptions)
| Shares Applied | Applicants | Allottees | Expected Lots |
|---|---|---|---|
| 200 | 4,146 | 4,146 | 1.00 |
| 400 | 350 | 175 | 1.50 |
| 600 | 144 | 144 | 2.00 |
| 800 | 76 | 32 | 2.42 |
| 1,000 | 146 | 146 | 3.00 |
| 1,200 | 33 | 15 | 3.45 |
| 1,400 | 29 | 29 | 4.00 |
| 1,600 | 138 | 62 | 4.45 |
| 1,800 | 29 | 29 | 5.00 |
| 2,000 | 125 | 46 | 5.37 |
| 3,000 | 64 | 64 | 7.00 |
| 4,000 | 24 | 24 | 9.00 |
| 5,000 | 20 | 20 | 11.00 |
| 6,000 | 15 | 15 | 13.00 |
| 7,000 | 24 | 24 | 15.00 |
| 8,000 | 9 | 9 | 17.00 |
| 9,000 | 5 | 5 | 19.00 |
| 10,000 | 23 | 23 | 21.00 |
| 15,000 | 6 | 6 | 24.00 |
| 20,000 | 17 | 17 | 27.00 |
| 25,000 | 5 | 5 | 30.00 |
| 30,000 | 5 | 5 | 33.00 |
| 35,000 | 2 | 2 | 36.00 |
| 40,000 | 2 | 2 | 39.00 |
| 45,000 | 1 | 1 | 42.01 |
| 50,000 | 2 | 2 | 45.00 |
| 60,000 | 2 | 2 | 51.99 |
| 70,000 | 2 | 2 | 59.01 |
| 90,000 | 1 | 1 | 72.99 |
| 100,000 | 5 | 5 | 80.00 |
Allotment Benchmarks
